Month: February 2021

NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 4, 2021. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, Daniel Luckshire, Chief Financial Officer, and Dr. Dennis Hruby, Chief Scientific Officer.A live webcast of the call will be available on the Company’s website at www.siga.com under the ‘Events & Presentations’ tab in the Investor Relations section, or by clicking here. Participants may also access the call by dialing 877-407-6184 for domestic callers or 201-389-0877 for international callers. Please log in approximately 5-10...

PORTLAND, Ore., Feb. 26, 2021 (GLOBE NEWSWIRE) — Golden Leaf Holdings Ltd. (CSE: GLH) (OTCQB: GLDFF) (“Golden Leaf,” “GLH” or the “Company”), a premier, consumer-driven cannabis company specializing in retail, production, processing, wholesale and distribution, today announces it has signed a non-binding letter of intent to acquire a multi store chain in the Northwest Oregon. These stores are expected to generate at least US$10 million in annual run rate revenue (based on unaudited January 2021 results) and had a net operating margin of 11% (unaudited) during fiscal 2020 (under U.S. GAAP).“We will announce further details about this transaction upon the signing of a definitive purchase agreement,” commented John Varghese, Golden Leaf Executive Chairman.The Company currently anticipates that the consideration for the acquisition...

Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapySOUTH SAN FRANCISCO, Calif., and WARMINSTER, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced the initiation of a Phase 2 clinical trial of Assembly Bio’s investigational hepatitis B virus (HBV) core inhibitor candidate, also known as a capsid inhibitor, vebicorvir (VBR), in combination with Arbutus’ proprietary GalNAc delivered RNAi therapeutic candidate, AB-729, and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy for the treatment of patients with chronic HBV infection. The companies announced a clinical collaboration agreement in August 2020.The randomized,...

SAN FRANCISCO, Feb. 26, 2021 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the “Company” or “Kalytera“) today announced that its shares will resume trading today on the TSX VENTURE EXCHANGE (“TSXV”).The Company also announced that, pending TSXV approval, it will change its name to Claritas Pharmaceuticals, Inc.The Company is also pleased to announce the launch of its new website at http://www.claritaspharma.com/.The decision to rename the Company signals the re-launch of the Company, and its intent to focus on the development of its proprietary drug, R-107, for the treatment of vaccine-resistant strains of COVID-19 as well as other viral infections. R-107 is a nitric oxide releasing molecule designed to treat vaccine-resistant COVID-19 infection as well as the...

HAMILTON, Bermuda, Feb. 26, 2021 (GLOBE NEWSWIRE) — Enstar Group Limited (NASDAQ: ESGR) hat heute bekanntgegeben, dass eine ihrer hundertprozentigen Tochtergesellschaften eine Vereinbarung zur Bereitstellung von Adverse Development Cover (ADC) für AXA XL, einer Abteilung von AXA, unterzeichnet hat.Im Rahmen der Transaktion deckt die Tochtergesellschaft von Enstar Verluste vor und bis einschließlich 31. Dezember 2019 für einen diversifizierten Mix aus globalen Privat- und Berufshaftpflichtschäden. Die Prämie entspricht der Übertragung von Schadenrückstellungen in Höhe von 90 % von 1.550 Milliarden US-Dollar (respektive 1.395 Milliarden US-Dollar).Die Tochtergesellschaft von Enstar bietet 90 % Schutz (AXA XL übernimmt 10 %) auf zwei Ebenen. Die erste bietet eine Deckung von 1.550 Milliarden US-Dollar nach einem Selbstbehalt in Höhe...

TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) — Skylight Health Group Inc (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), one of the largest multi-specialty healthcare systems in the United States, is pleased to announce the appointment of Andrew Elinesky as Chief Financial Officer.Mr. Elinesky has a long and distinguished career in Finance and has served as CFO for multiple publicly traded companies in Canada and the United States. He comes with strong cross-border market experience and specializes in M&A and consolidation.Former SVP and CFO at McEwen Mining, a SEC registered multinational mining company listed on the NYSE and TSX with properties and operations in Canada, Argentina, Mexico, and the United Sates. Mr. Elinesky developed and implemented all aspects of company financial strategy, including respective...

LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex (TSC), for patients two years of age and older.TSC is a condition that causes mostly benign tumours to grow in vital organs of the body, including the brain, skin, heart, eyes, kidneys and lungs, and in which epilepsy is the most common neurological feature. TSC is typically diagnosed in childhood.1“Epilepsy is reported...

LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex (TSC), for patients two years of age and older.TSC is a condition that causes mostly benign tumours to grow in vital organs of the body, including the brain, skin, heart, eyes, kidneys and lungs, and in which epilepsy is the most common neurological feature. TSC is typically diagnosed in childhood.1“Epilepsy is reported...

WOODBRIDGE, N.J., Feb. 26, 2021 (GLOBE NEWSWIRE) — NORTHFIELD BANCORP, INC. (NasdaqGS: NFBK), the holding company for Northfield Bank, collectively, the “Company,” announced that John W. Alexander, Chairman of Board, has advised the Company’s Boards of Directors that he will be retiring from the boards following the Annual Meeting of Stockholders on May 26, 2021. The Boards of the Company have selected Steven M. Klein, President & Chief Executive Officer to succeed Mr. Alexander as Chairman following his retirement.Annette Catino, Lead Independent Director, commented, “During Mr. Alexander’s over 20-year tenure as Chairman and Chief Executive Officer, and for more than three years as Chairman of the Board following his retirement as CEO, Northfield has had an enviable record of performance and has built significant value for...

CHMP has completed a review of available data for investigational antibody cocktail casirivimab and imdevimab (REGN-COV2) to be considered for the treatment of confirmed COVID-19  CHMP scientific opinion supports national decision making within EU states on the use of the antibodies before a formal authorisation is granted during a public health emergencyRoche and Regeneron are collaborating on developing and manufacturing casirivimab and imdevimab; Roche will be responsible for distribution in Europe and other countries outside the USBasel, 26 February 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) confirmed today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a scientific opinion supporting the use of the investigational antibody cocktail, casirivimab and imdevimab, as a...